Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NASDAQ:HOWL NYSE:NNVC NASDAQ:RNTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.96+1.5%$6.64$5.41▼$12.05$8.56M1.515,614 shs290 shsHOWLWerewolf Therapeutics$0.65-2.0%$0.81$0.53▼$2.38$31.44M0.41433,219 shs283,044 shsNNVCNanoViricides$1.43-4.0%$1.12$0.85▼$2.23$30.88M1.54275,898 shs138,765 shsRNTXRein Therapeutics$1.08-6.5%$1.38$1.00▼$2.40$30.20M1.42384,399 shs141,789 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-1.23%-4.94%+4.68%-13.10%-16.85%HOWLWerewolf Therapeutics-2.87%-8.64%-22.20%-7.97%-17.42%NNVCNanoViricides-3.87%+14.62%+51.62%+47.52%+12.88%RNTXRein Therapeutics-5.74%+11.65%-22.82%+0.88%-34.66%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$6.96+1.5%$6.64$5.41▼$12.05$8.56M1.515,614 shs290 shsHOWLWerewolf Therapeutics$0.65-2.0%$0.81$0.53▼$2.38$31.44M0.41433,219 shs283,044 shsNNVCNanoViricides$1.43-4.0%$1.12$0.85▼$2.23$30.88M1.54275,898 shs138,765 shsRNTXRein Therapeutics$1.08-6.5%$1.38$1.00▼$2.40$30.20M1.42384,399 shs141,789 shs5G Stocks: The Path Forward is ProfitableClick the link to see MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-1.23%-4.94%+4.68%-13.10%-16.85%HOWLWerewolf Therapeutics-2.87%-8.64%-22.20%-7.97%-17.42%NNVCNanoViricides-3.87%+14.62%+51.62%+47.52%+12.88%RNTXRein Therapeutics-5.74%+11.65%-22.82%+0.88%-34.66%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 1.00SellN/AN/AHOWLWerewolf Therapeutics 2.14Hold$3.75479.60% UpsideNNVCNanoViricides 3.00BuyN/AN/ARNTXRein Therapeutics 2.00Hold$8.00644.19% UpsideCurrent Analyst Ratings BreakdownLatest ADXN, HOWL, RNTX, and NNVC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/20/2026HOWLWerewolf Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/8/2026ADXNAddex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 5/12/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$460K18.61N/AN/A$10.37 per share0.67HOWLWerewolf TherapeuticsN/AN/AN/AN/A$0.51 per shareN/ANNVCNanoViricidesN/AN/AN/AN/A$0.66 per shareN/ARNTXRein TherapeuticsN/AN/A$0.05 per share21.34($1.07) per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics$8.02M-$5.74N/AN/AN/AN/A-80.69%-69.69%5/25/2026 (Estimated)HOWLWerewolf Therapeutics-$60.82M-$1.24N/AN/AN/AN/A-176.04%-69.87%N/ANNVCNanoViricides-$8.29M-$0.48N/AN/AN/AN/A-87.90%-78.69%N/ARNTXRein Therapeutics-$49.87M-$1.96N/AN/AN/AN/A-510.35%-56.38%N/ALatest ADXN, HOWL, RNTX, and NNVC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026HOWLWerewolf Therapeutics-$0.32-$0.28+$0.04-$0.28N/AN/A3/27/2026Q4 2025HOWLWerewolf Therapeutics-$0.34-$0.20+$0.14-$0.20$0.30 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AHOWLWerewolf TherapeuticsN/AN/AN/AN/AN/ANNVCNanoViricidesN/AN/AN/AN/AN/ARNTXRein TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A2.012.01HOWLWerewolf TherapeuticsN/A1.621.62NNVCNanoViricidesN/A3.442.47RNTXRein TherapeuticsN/A0.700.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%HOWLWerewolf Therapeutics64.84%NNVCNanoViricides10.30%RNTXRein Therapeutics90.89%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%HOWLWerewolf Therapeutics23.60%NNVCNanoViricides3.60%RNTXRein Therapeutics5.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.23 million1.05 millionNot OptionableHOWLWerewolf Therapeutics4048.60 million37.13 millionOptionableNNVCNanoViricides2021.60 million14.92 millionOptionableRNTXRein Therapeutics928.04 million26.61 millionN/AADXN, HOWL, RNTX, and NNVC HeadlinesRecent News About These CompaniesRein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common StockApril 30, 2026 | globenewswire.comRein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary FibrosisApril 29, 2026 | globenewswire.comRein Therapeutics Inc. (NASDAQ:RNTX) Short Interest Down 51.4% in AprilApril 26, 2026 | marketbeat.comRein Therapeutics Stock Short Interest Report | NASDAQ:RNTX | BenzingaApril 14, 2026 | benzinga.comRein Therapeutics Doses First Patient in Phase 2 Trial of LTI-03 for Idiopathic Pulmonary FibrosisMarch 3, 2026 | markets.businessinsider.comRein Therapeutics (RNTX) price target increased by 25.00% to 10.20February 4, 2026 | msn.comAnalysts Offer Insights on Healthcare Companies: Rein Therapeutics (RNTX), Zimmer Biomet Holdings (ZBH) and Theravance Biopharma (TBPH)January 23, 2026 | theglobeandmail.comRein Therapeutics Receives Orphan Drug Designation from European Medicines Agency for Lead Drug Candidate in Idiopathic Pulmonary FibrosisJanuary 20, 2026 | manilatimes.netMRein Therapeutics (NASDAQ:RNTX) Shares Down 0.8% – Here’s WhyJanuary 9, 2026 | defenseworld.netDVoss Capital, Lp Buys 104,183 Shares of Rein Therapeutics (NASDAQ:RNTX) StockNovember 19, 2025 | insidertrades.comRein Therapeutics (RNTX) Price Target Decreased by 20.00% to 8.16November 17, 2025 | msn.comRein Therapeutics Announces New Scientific Publication Demonstrating LTI-03 May Reduce Lung Scarring and Protect Cells Needed for Lung Repair in IPFNovember 6, 2025 | finance.yahoo.comRein Therapeutics upgraded to Buy from Hold at BrooklineNovember 4, 2025 | msn.comWhy Is Rein Therapeutics Stock Trading Higher On Monday?November 3, 2025 | benzinga.comRein Therapeutics Receives FDA Clearance to Resume U.S. Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisNovember 3, 2025 | taiwannews.com.twTRein Therapeutics Inc. Stock (RNTX) Opinions on Institutional Investments and Funding DealsOctober 29, 2025 | quiverquant.comQInsider Buying: Rein Therapeutics (NASDAQ:RNTX) Major Shareholder Purchases 30,176 Shares of StockOctober 29, 2025 | insidertrades.comRein Therapeutics Receives European Regulatory Approval to Initiate Phase 2 Trial of LTI-03 in Idiopathic Pulmonary FibrosisOctober 9, 2025 | globenewswire.comRein Therapeutics (RNTX) Price Target Increased by 42.86% to 10.20October 1, 2025 | msn.comHC Wainwright & Co. Initiates Coverage of Rein Therapeutics (RNTX) with Buy RecommendationSeptember 22, 2025 | msn.comRein Therapeutics initiated with a Buy at H.C. WainwrightSeptember 22, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXN, HOWL, RNTX, and NNVC Company DescriptionsAddex Therapeutics NASDAQ:ADXN$6.96 +0.10 (+1.47%) As of 12:20 PM Eastern This is a fair market value price provided by Massive. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Werewolf Therapeutics NASDAQ:HOWL$0.65 -0.01 (-2.04%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I/Ib clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an activated Interleukin-21(IL-21) and WTX-518, an activated IL-18 (IL-18) INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.NanoViricides NYSE:NNVC$1.43 -0.06 (-4.03%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.Rein Therapeutics NASDAQ:RNTX$1.08 -0.08 (-6.52%) As of 12:49 PM Eastern This is a fair market value price provided by Massive. Learn more.Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Sony's $4 Billion Bet on Rock & Roll Royalties Ubiquiti’s Uptrend Can Continue, But Don’t Rush to Buy It AI Demand Fuels Strong Q1 Earnings for Constellation Energy TMC Forges a New EV Supply Chain at the Bottom of the Sea MercadoLibre Boldly Invests in Growth: Discount Deepens Manic Monday.com: The Rally Is Just the Beginning for this SaaS Leader 5 Stocks Positioned to Benefit From the AI Inference Boom Sell in May and Go Away—Starting With These 3 Stocks Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
